eligibility_summary
Adults 18–75, ECOG ≤1, life expectancy >3 mo, HER2‑negative recurrent/metastatic breast cancer not curable by surgery/radiation, tumor tissue available, prior failure of ≥1 chemo (HR+ also CDK4/6+endocrine), progression on last therapy, RECIST‑measurable disease, adequate organs, contraception, not pregnant/lactating. Exclude recent anti‑cancer Rx/trial drugs, other malignancy, >G1 toxicities, recent surgery/trauma, ILD/thrombosis, CNS mets, uncontrolled effusions, vessel invasion, or allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: TQB2102 for injection, a targeted biologic HER2 dual–antibody-drug conjugate (ADC), dosed 7.5 mg/kg IV every 3 weeks. Mechanism: two anti-HER2 antibody components bind HER2 (ERBB2) on tumor cells, promote receptor-mediated internalization, and release an intracellular cytotoxic payload to induce tumor cell death, binding may also inhibit HER2 signaling. Targets: HER2/ERBB2 on breast cancer cells (in a HER2‑negative/metastatic population by standard pathology), impacting HER family signaling pathways and leveraging ADC payload-mediated cytotoxicity.